Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTL NASDAQ:GRI NASDAQ:VIVS NASDAQ:VRAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTLArtelo Biosciences$1.43-2.1%$3.94$1.19▼$85.80$3.33M-0.132.58 million shs431,716 shsGRIGRI Bio$2.13+6.0%$2.28$1.97▼$80.36$3.77M-1.17247,329 shs34,003 shsVIVSVivoSim Labs$1.35+7.1%$1.45$1.22▼$5.30$3.52M1.38981,613 shs114,787 shsVRAXVirax Biolabs Group$0.20-17.5%$0.18$0.10▼$1.14$860K1.2618.18 million shs2.82 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTLArtelo Biosciences+0.69%+7.35%-56.93%-58.40%-92.34%GRIGRI Bio0.00%-4.29%-7.80%-16.25%-94.68%VIVSVivoSim Labs-1.56%-2.33%-12.50%-32.98%-29.01%VRAXVirax Biolabs Group+11.00%+9.53%+82.17%+15.99%-75.99%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTLArtelo Biosciences$1.43-2.1%$3.94$1.19▼$85.80$3.33M-0.132.58 million shs431,716 shsGRIGRI Bio$2.13+6.0%$2.28$1.97▼$80.36$3.77M-1.17247,329 shs34,003 shsVIVSVivoSim Labs$1.35+7.1%$1.45$1.22▼$5.30$3.52M1.38981,613 shs114,787 shsVRAXVirax Biolabs Group$0.20-17.5%$0.18$0.10▼$1.14$860K1.2618.18 million shs2.82 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTLArtelo Biosciences+0.69%+7.35%-56.93%-58.40%-92.34%GRIGRI Bio0.00%-4.29%-7.80%-16.25%-94.68%VIVSVivoSim Labs-1.56%-2.33%-12.50%-32.98%-29.01%VRAXVirax Biolabs Group+11.00%+9.53%+82.17%+15.99%-75.99%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTLArtelo Biosciences 1.67Reduce$54.003,676.22% UpsideGRIGRI Bio 2.33Hold$32.001,402.35% UpsideVIVSVivoSim Labs 1.00SellN/AN/AVRAXVirax Biolabs Group 2.00Hold$1.00404.80% UpsideCurrent Analyst Ratings BreakdownLatest VRAX, GRI, ARTL, and VIVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026GRIGRI Bio Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$40.00 ➝ $32.005/22/2026VIVSVivoSim Labs Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/7/2026VIVSVivoSim Labs Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026GRIGRI Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026VRAXVirax Biolabs Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026ARTLArtelo Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTLArtelo BiosciencesN/AN/AN/AN/A($1.89) per shareN/AGRIGRI BioN/AN/AN/AN/A$4.16 per shareN/AVIVSVivoSim Labs$140K25.17N/AN/A$5.54 per share0.24VRAXVirax Biolabs Group$10K85.98N/AN/A$1.26 per share0.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTLArtelo Biosciences-$12.88M-$32.74N/AN/AN/AN/A-1,600.12%-224.62%8/12/2026 (Estimated)GRIGRI Bio-$11.96M-$74.16N/AN/AN/AN/A-199.52%-143.23%8/13/2026 (Estimated)VIVSVivoSim Labs-$2.48M-$3.15N/AN/AN/A-861.27%-15.51%-11.31%N/AVRAXVirax Biolabs Group-$6.06MN/AN/AN/AN/AN/AN/AN/AN/ALatest VRAX, GRI, ARTL, and VIVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026ARTLArtelo Biosciences-$0.78-$4.00-$3.22-$4.00N/AN/A5/13/2026Q1 2026GRIGRI Bio-$1.6050-$1.61-$0.0050-$1.61N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARTLArtelo BiosciencesN/AN/AN/AN/AN/AGRIGRI BioN/AN/AN/AN/AN/AVIVSVivoSim LabsN/AN/AN/AN/AN/AVRAXVirax Biolabs GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTLArtelo BiosciencesN/A1.791.79GRIGRI BioN/A14.2014.21VIVSVivoSim LabsN/A2.442.44VRAXVirax Biolabs GroupN/A11.3711.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTLArtelo Biosciences0.87%GRIGRI Bio33.95%VIVSVivoSim Labs8.23%VRAXVirax Biolabs Group8.61%Insider OwnershipCompanyInsider OwnershipARTLArtelo Biosciences11.50%GRIGRI Bio8.73%VIVSVivoSim Labs2.50%VRAXVirax Biolabs Group45.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTLArtelo Biosciences52.33 million2.07 millionNot OptionableGRIGRI Bio11.77 million1.62 millionNot OptionableVIVSVivoSim Labs202.61 million2.54 millionN/AVRAXVirax Biolabs Group54.34 million2.38 millionNot OptionableVRAX, GRI, ARTL, and VIVS HeadlinesRecent News About These CompaniesVirax Biolabs Group (VRAX) Projected to Post Earnings on WednesdayMay 27, 2026 | americanbankingnews.comVirax BioLabs Group Limited: Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune in Long COVID and Related Post-Acute Infection SyndromesMay 26, 2026 | finanznachrichten.deVirax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection SyndromesMay 26, 2026 | prnewswire.comVirax Biolabs Calls June 5 EGM to Approve Reverse Share Split and Charter AmendmentsMay 22, 2026 | tipranks.comWhy Is Virax Biolabs (VRAX) Stock Trending Overnight?May 19, 2026 | benzinga.comVirax Biolabs (VRAX) surges 177% as low-float momentum meets extreme short interestMay 18, 2026 | quiverquant.comQAvalon Advanced Materials and Virax Biolabs Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVMay 15, 2026 | corsicanadailysun.comCVirax Biolabs Group Ltd - Ordinary Shares - Class AMay 13, 2026 | money.usnews.comVirax Biolabs Group Limited Or Stock Short Interest Rises to 71.68%April 25, 2026 | quiverquant.comQVirax Biolabs Group Ltd. Class AApril 24, 2026 | edition.cnn.comVirax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to ShareholdersApril 14, 2026 | prnewswire.comVirax Biolabs Announces Full Exercise of Pre-Funded Warrants From $5 Million Private PlacementApril 10, 2026 | tipranks.comWhat's Behind The Jump In Virax Biolabs Stock?March 31, 2026 | benzinga.comVirax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical ValidationMarch 31, 2026 | prnewswire.comVirax Biolabs Group (VRAX) price target decreased by 95.00% to 1.02February 5, 2026 | msn.comVirax Biolabs Sets March 11, 2026 AGM to Vote on Reverse Share Split and New Equity PlanJanuary 30, 2026 | tipranks.comVirax Biolabs Group Limited (VRAX) Upgraded to Buy: Here's WhyJanuary 15, 2026 | zacks.comVirax Biolabs secures $5 million in private placement to advance immunology researchDecember 4, 2025 | msn.comVirax Biolabs Group Limited Announces Closing of $5 Million Private PlacementDecember 4, 2025 | prnewswire.comVirax Biolabs Group Limited Announces $5 Million Private PlacementDecember 3, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026IREN Is Flipping the Switch from Bitcoin to AIBy Jeffrey Neal Johnson | May 28, 2026The Power Grid Is Dying—Is It Time to Buy Its Replacement?By Jeffrey Neal Johnson | May 15, 2026The USMCA Review Is Coming: 3 Border-Sensitive Stocks to WatchBy Chris Markoch | May 8, 2026Deere Beats Q2 Estimates, But Ag Weakness Weighs on OutlookBy Chris Markoch | May 22, 2026VRAX, GRI, ARTL, and VIVS Company DescriptionsArtelo Biosciences NASDAQ:ARTL$1.43 -0.03 (-2.05%) Closing price 04:00 PM EasternExtended Trading$1.43 0.00 (0.00%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.GRI Bio NASDAQ:GRI$2.13 +0.12 (+5.97%) Closing price 03:59 PM EasternExtended Trading$2.09 -0.04 (-2.07%) As of 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.VivoSim Labs NASDAQ:VIVS$1.35 +0.09 (+7.14%) Closing price 04:00 PM EasternExtended Trading$1.32 -0.04 (-2.59%) As of 04:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.Virax Biolabs Group NASDAQ:VRAX$0.20 -0.04 (-17.49%) Closing price 04:00 PM EasternExtended Trading$0.20 0.00 (-1.06%) As of 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand Medtronic Bottoms, Healthy Rebound Ahead From Runway to Riches: Victoria's Secret's New Look Coke's $10B India IPO Plan Pops the Top on Hidden Value Dell's AI Toll Bridge Is Paved with Record Margins The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker GitLab’s Price Recovery Gains Traction—Time to Get On Board? Ulta's Q1 Report Primes It for a Beauty of a Rebound Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
